Showing 3281-3290 of 4186 results for "".
- Aclaris Acquires Rhofade from Allerganhttps://practicaldermatology.com/news/aclaris-acquires-rhofade-from-allergan/2457561/Aclaris Therapeutics, Inc. has entered into a definitive asset purchase agreement with Allergan Sales, LLC to acquire worldwide rights to Rhofade® (oxymetazoline hydrochloride) cream, 1% and additional intellectual property. The acquisition includes an exclusive license to certain intel
- Psoriasis Plus Hypertension Equals Greater Need for Heart Surgeryhttps://practicaldermatology.com/news/psoriasis-plus-hypertension-equals-greater-need-for-cardiovascular-interventions/2457559/Patients with psoriasis and hypertension need more cardiovascular procedures and surgeries than hypertensive patients without psoriasis, a new study in the Journal of Dermatology suggests. In 5.62 year
- ASDS Announces 2018 President's Award Recipientshttps://practicaldermatology.com/news/asds-announces-2018-presidents-award-recipients/2457565/In her final act as president this week, Lisa M. Donofrio, MD, recognizes four members of the American Society for Dermatologic Surgery (ASDS) with the President’s Award at the Society’s Annual Meeting. “One of the wonderful gifts about being president of an organization
- Endo Presents Data on the Perception and Measurement of Cellulite Severity at ASDS Meetinghttps://practicaldermatology.com/news/endo-presents-data-on-the-perception-and-measurement-of-cellulite-severity-at-asds-meeting/2457568/The new Clinician Reported Photonumeric Cellulite Severity Scale (CR-PCSS) is a reliable tool for evaluating cellulite severity of the buttocks and thighs and correlates well with the Patient Reported Photonumeric Cellulite Severity Scale, according to research presented by
- Pre-conditioning Added to Sebacia Microparticles Enhances Outcomeshttps://practicaldermatology.com/news/pre-conditioning-added-to-sebacia-microparticles-enhances-outcomes/2457567/Using pre-conditioning in conjunction with Sebacia Microparticles for treatment of acne leads to enhanced outcomes, new data suggest. In fact, results from a real-world, pre-conditioning registry trial in Europe demonstrate that the combination of pre-conditioning followed by Sebacia Mi
- Online Care May Be As Effective as In-Person Care for Psoriasishttps://practicaldermatology.com/news/online-care-may-be-as-effective-as-in-person-care-for-psoriasis/2457574/Teledermatology may be as effective as seeing a doctor in person when it comes to improving the symptoms of psoriasis, according to a new study in JAMA Network Open. “Patients with chronic skin diseases need ongoing care, and depending on where they live, their access to de
- Acne Stigma Linked to Lower Overall Q of Lhttps://practicaldermatology.com/news/acne-stigma-linked-to-lower-overall-q-of-l/2457578/Acne patients perceived social stigma negatively affects their quality of life, according to a new study from the University of Limerick. In the survey of 271 people with acne, those whose negative perceptions of how society viewed their appearance had higher psychological distress levels
- Seysara: Oral Antibiotic is First Approved for Dermatology in 40 Yearshttps://practicaldermatology.com/news/seysara-oral-antibiotic-is-first-approved-for-dermatology-in-40-years/2457584/Seysara (sarecycline), a new, first in class tetracycline-derived oral antibiotic, is now approved for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 9 years of age and older. Almirall, which recently acquired Seysara from Allergan, plans to laun
- Recros Medica Unveils the Nuvellus Brand for Its Novel Rotational Fractional Resection Technologyhttps://practicaldermatology.com/news/recros-medica-unveils-the-nuvellus-brand-for-its-novel-rotational-fractional-resection-technology/2457588/Recros Medica, Inc. is unveiling the Nuvellus brand at this week’s American Society of Plastic Surgery meeting. The company will display at booth #1264, where it will introduce Nuvellus as an innovative, minimally-invasive surgical procedure in develop
- FDA Approves Regeneron's Libtayo, First Treatment for Metastatic or Locally Advanced SCChttps://practicaldermatology.com/news/fda-approves-regenerons-libtayo-first-treatment-for-metastatic-or-locally-advanced-scc/2457589/Libtayo (cemiplimab-rwlc) injection (Regeneron Pharmaceuticals, Inc.) is now FDA-approved for intravenous use for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiatio